secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOTRICITY INC. (BTCY)
CIK:        0001630113
Form:       8-K
Filed at:   2021-12-08T23:59:59+00:00
Accession:  0001493152-21-030839
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biotricity CEO letter cites record Q2 revenue of $1.81M (+143% YoY), sets 2022 goals
--------------------------------------------------------------------------------

- Record quarterly revenue of $1.81M for Q2 FY2022 ended Sep 30, 2021, up 143% YoY, tenth consecutive triple-digit growth quarter.
- Recent uplisting to Nasdaq to attract larger investor pool and increase liquidity.
- Introduced Biokit, a 3-device personal medical kit for integration into Biotricity ecosystem.
- Product roadmap includes Bioflux, Biotres, Biocare Telemed, and Bioheart.
- 2022 goals: launch new cardiac monitoring solutions and software services to become turnkey cardiac health provider.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630113/000149315221030839/0001493152-21-030839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630113/000149315221030839/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-030839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer